Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Madrigal Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company develops novel and small-molecule drugs addressing cardiovascular and metabolic diseases. Madrigal Pharmaceuticals offers its services in the United States.
Website: madrigalpharma.com


  • Good financial results growth rate 100.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (8.3%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 1.3% (LTM)
  • Share price is 404.6% higher than minimum and 17.2% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders sold company shares on $24.3 mln (-0.383% of cap.)

Key Financials (Download financials)

Ticker: MDGL
Share price, USD:  (-1.6%)294.64
year average price 287.29  


year start price 205.25 2024-05-11

min close price 202.47 2024-10-23

max close price 355.88 2025-02-26

current price 294.64 2025-05-10
Common stocks: 18 476 414

Dividend Yield:  0.0%
EV / Sales: 652.7x
Margin (EBITDA LTM / Revenue): -4 337.5%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 5 444
Net Debt ($m): -222
EV (Enterprise Value): 5 222
EBITDA LTM (млн $): -347
Price to Book: 7.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-05-01zacks.com

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

2025-02-26zacks.com

Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

2025-02-26seekingalpha.com

Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript

2025-02-26zacks.com

Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates

2025-01-19seekingalpha.com

Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH

2025-01-15zacks.com

MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales

2025-01-13fool.com

Why Madrigal Pharmaceuticals Stock Is Sinking Today

2025-01-13globenewswire.com

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

2025-01-09seekingalpha.com

Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion

2024-11-22zacks.com

Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-31 2024-08-07 2024-05-07 2024-02-28 2023-11-06 2023-08-08 2023-05-09 2023-02-23 2022-11-03
acceptedDate 2024-10-31 09:02:50 2024-08-07 08:58:48 2024-05-07 09:00:37 2024-02-28 06:32:35 2023-11-06 06:10:12 2023-08-08 06:50:49 2023-05-09 06:51:22 2023-02-23 06:32:29 2022-11-03 08:56:24
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 62M 15M 0 0 0 0 0 0 0
costOfRevenue 2M 903 000 168 000 142 000 135 000 126 000 0 0 0
grossProfit 60M 14M -168 000 -142 000 -135 000 -126 000 0 0 0
grossProfitRatio 0.965 0.938 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 69M 71M 71M 70M 71M 69M 62M 71M 68M
generalAndAdministrativeExpenses 108M 105M 81M 47M 28M 18M 16M 15M 12M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 108M 105M 81M 47M 28M 18M 16M 15M 12M
otherExpenses 0 0 0 0 0 0 0 0 0
operatingExpenses 176M 176M 152M 117M 99M 86M 78M 85M 80M
costAndExpenses 178M 177M 152M 117M 99M 86M 78M 85M 80M
interestIncome 13M 14M 8M 9M 3M 4M 4M 1M 717 000
interestExpense 4M 4M 4M 4M -4M 3M 2M 2M 2M
depreciationAndAmortization 298 000 267 000 168 000 142 000 135 000 126 000 4M 1M 838 000
ebitda -103M -148M -152M -117M -99M -83M -74M -84M -80M
ebitdaratio -1.656 -11.086 0 0 0 0 0 0 0
operatingIncome -116M -163M -152M -117M -99M -86M -78M -85M -80M
operatingIncomeRatio -1.871 -11.104 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet 9M 11M 4M 5M -206 000 650 000 1M -606 000 -785 000
incomeBeforeTax -107M -152M -148M -112M -99M -86M -77M -86M -81M
incomeBeforeTaxRatio -1.72 -10.382 0 0 0 0 0 0 0
incomeTaxExpense 0 0 0 98 188 -135 000 3M 896 000 2M 2M
netIncome -107M -152M -148M -112M -99M -86M -78M -88M -83M
netIncomeRatio -1.72 -10.382 0 0 0 0 0 0 0
eps -4.92 -7.1 -7.38 -5.68 -5.34 -4.69 -4.28 -5.08 -4.84
epsdiluted -4.92 -7.1 -7.38 -5.68 -5.34 -4.69 -4.28 -5.08 -4.84
weightedAverageShsOut 22M 21M 20M 20M 18M 18M 18M 17M 17M
weightedAverageShsOutDil 22M 21M 20M 20M 18M 18M 18M 17M 17M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-31 2024-08-07 2024-05-07 2024-02-28 2023-11-06 2023-08-08 2023-05-09 2023-02-23 2022-11-03
acceptedDate 2024-10-31 09:02:50 2024-08-07 08:58:48 2024-05-07 09:00:37 2024-02-28 06:32:35 2023-11-06 06:10:12 2023-08-08 06:50:49 2023-05-09 06:51:22 2023-02-23 06:32:29 2022-11-03 08:56:24
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 233M 500M 623M 100M 62M 77M 113M 332M 59M
shortTermInvestments 766M 563M 437M 534M 170M 221M 216M 27M 94M
cashAndShortTermInvestments 999M 1 063M 1 059M 634M 232M 298M 329M 359M 153M
netReceivables 30M 7M 1 0 0 0 0 0 0
inventory 9M 7M 854 000 0 0 0 0 0 0
otherCurrentAssets 26M 20M 14M 3M 3M 3M 2M 3M 4M
totalCurrentAssets 1 064M 1 092M 1 074M 637M 235M 302M 331M 361M 157M
propertyPlantEquipmentNet 5M 3M 3M 3M 2M 866 000 1M 1M 2M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 5M 5M 5M 0 0 0 0 0 0
goodwillAndIntangibleAssets 5M 5M 5M 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 0 -1 -1 0 0 0 0 0 0
totalNonCurrentAssets 10M 8M 8M 3M 2M 866 000 1M 1M 2M
otherAssets 0 1 1 -0 0 0 0 0 0
totalAssets 1 073M 1 100M 1 082M 641M 238M 302M 332M 363M 159M
accountPayables 46M 9M 22M 28M 17M 18M 12M 24M 19M
shortTermDebt 878 000 557 000 542 000 527 000 513 000 411 000 653 000 602 000 760 000
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 131M 116M 92M 90M 83M 82M 86M 91M 80M
totalCurrentLiabilities 178M 125M 114M 119M 100M 100M 98M 116M 99M
longTermDebt 118M 118M 116M 115M 116M 99M 84M 49M 49M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 1M 1M 0 0 0 0 30M
totalNonCurrentLiabilities 118M 118M 117M 117M 116M 99M 84M 49M 49M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 1M 1M 1M 1M 2M 411 000 653 000 602 000 831 000
totalLiabilities 296M 243M 232M 235M 216M 199M 182M 165M 148M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 2000 2000 2000 2000 2000 2000 2000 2000 2000
retainedEarnings -1 743M -1 636M -1 484M -1 336M -1 224M -1 125M -1 040M -963M -877M
accumulatedOtherComprehensiveIncomeLoss 1M -368 000 -172 000 468 000 -42 000 -89 000 -86 000 -32 000 -237 000
othertotalStockholdersEquity 2 519M 2 493M 2 335M 1 741M 1 246M 1 229M 1 190M 1 160M 888M
totalStockholdersEquity 777M 857M 851M 405M 22M 104M 150M 197M 11M
totalEquity 777M 857M 851M 405M 22M 104M 150M 197M 11M
totalLiabilitiesAndStockholdersEquity 1 073M 1 100M 1 082M 641M 238M 302M 332M 363M 159M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 073M 1 100M 1 082M 641M 238M 302M 332M 363M 159M
totalInvestments 766M 563M 437M 534M 170M 221M 216M 27M 94M
totalDebt 119M 118M 118M 117M 117M 100M 85M 50M 50M
netDebt -114M -382M -505M 17M 55M 22M -29M -282M -10M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-31 2024-08-07 2024-05-07 2024-02-28 2023-11-06 2023-08-08 2023-05-09 2023-02-23 2022-11-03
acceptedDate 2024-10-31 09:02:50 2024-08-07 08:58:48 2024-05-07 09:00:37 2024-02-28 06:32:35 2023-11-06 06:10:12 2023-08-08 06:50:49 2023-05-09 06:51:22 2023-02-23 06:32:29 2022-11-03 08:56:24
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -107M -152M -148M -112M -99M -86M -77M -86M -81M
depreciationAndAmortization 298 000 267 000 168 000 142 000 135 000 126 000 124 000 129 000 121 000
deferredIncomeTax 0 0 0 -4M 0 0 0 0 0
stockBasedCompensation 18M 24M 20M 15M 13M 11M 11M 8M 8M
changeInWorkingCapital 22M -8M -22M 17M 351 000 -1M -19M 19M 14M
accountsReceivables -24M -7M 0 0 0 0 0 0 0
inventory -2M -6M -854 000 0 0 0 0 0 0
accountsPayables 37M -8M -12M 11M -992 000 5M -12M 5M 7M
otherWorkingCapital 10M 13M -10M 5M 1M -7M 12M 14M 6M
otherNonCashItems 22 000 39M 33M 4M 674 000 554 000 433 000 306 000 313 000
netCashProvidedByOperatingActivities -67M -135M -149M -80M -85M -75M -84M -59M -59M
investmentsInPropertyPlantAndEquipment 4M -5M -357 000 -1M -339 000 -69 000 -35 000 -29 000 -33 000
acquisitionsNet 0 0 0 361 087 -50 538 3663 -2M -3000 0
purchasesOfInvestments -416M -281M -84M -475M -69M -92M -199M -13M -14M
salesMaturitiesOfInvestments 204M 164M 183M 114M 119M 88M 12M 79M 79M
otherInvestingActivites 6M -122M 98M -361 087 50 538 -3663 2M 3000 0
netCashUsedForInvestingActivites -202M -122M 98M -362M 50M -4M -187M 66M 65M
debtRepayment 0 0 0 0 -15M -15M 0 -886 000 0
commonStockIssued 7M 86M 574M 480M -21M 28M 18M 255M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 7M 48M 574M 479 916 56M 30M 35M 10M 0
netCashUsedProvidedByFinancingActivities 7M 134M 574M 480M 20M 43M 53M 264M 0
effectOfForexChangesOnCash 0 0 0 0 0 58M 0 0 0
netChangeInCash -262M -123M 523M 38M -15M -36M -218M 272M 6M
cashAtEndOfPeriod 238M 500M 623M 100M 62M 77M 113M 332M 59M
cashAtBeginningOfPeriod 500M 623M 100M 62M 77M 113M 332M 59M 53M
operatingCashFlow -67M -135M -149M -80M -85M -75M -84M -59M -59M
capitalExpenditure -779 000 -5M -357 000 -1M -339 000 -69 000 -35 000 -29 000 -33 000
freeCashFlow -68M -140M -150M -81M -85M -75M -84M -59M -59M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-08-07 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2022 q1
2022-05-09 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-31 11:00 ET
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
2024-10-30 12:00 ET
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
2024-10-21 12:00 ET
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis
2024-10-18 12:00 ET
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
2024-10-02 12:00 ET
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
2024-10-01 12:00 ET
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
2024-09-30 12:00 ET
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
2024-08-26 12:00 ET
Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-08-07 11:00 ET
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
2024-08-02 11:00 ET
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
2024-07-24 12:00 ET
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
2024-06-06 12:00 ET
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
2024-06-05 12:00 ET
Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-29 12:00 ET
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
2024-05-07 11:00 ET
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
2024-04-24 20:00 ET
Madrigal Statement on the Passing of Dr. Stephen Harrison
2024-04-23 12:00 ET
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
2024-04-16 20:05 ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-04-09 12:00 ET
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
2024-04-03 20:05 ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-03-19 03:58 ET
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
2024-03-19 03:58 ET
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
2024-03-18 20:04 ET
Madrigal Pharmaceuticals Announces Proposed Public Offering
2024-03-14 20:15 ET
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
2024-03-06 21:05 ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-03-05 13:00 ET
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
2024-02-28 12:01 ET
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
2024-02-28 12:00 ET
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-21 13:00 ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-02-08 13:00 ET
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine
2024-02-06 21:05 ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-01-29 13:00 ET
Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
2024-01-22 13:00 ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-01-04 13:00 ET
Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference
2024-01-03 21:30 ET
Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-22 21:30 ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2023-11-27 21:30 ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2023-11-21 13:00 ET
Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer
2023-11-15 21:45 ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2023-11-10 13:00 ET
Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health
2023-11-10 12:30 ET
Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer
2023-11-06 13:00 ET
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results
2023-11-02 20:05 ET
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
2023-10-12 20:05 ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2023-09-29 02:30 ET
Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering
2023-09-28 20:01 ET
Madrigal Pharmaceuticals Announces Proposed Public Offering
2023-09-14 20:30 ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2023-09-13 13:10 ET
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
2023-09-11 11:00 ET
Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer
2023-08-08 12:00 ET
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
2023-07-17 12:00 ET
Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
2023-06-30 12:00 ET
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
2023-06-22 07:30 ET
Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
2023-06-06 12:00 ET
Madrigal Pharmaceuticals Supports International NASH Day on June 8
2023-06-01 12:00 ET
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
2023-05-11 12:00 ET
Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
2023-05-09 12:00 ET
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
2023-04-18 12:00 ET
Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial
2023-02-23 13:00 ET
Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
2023-02-08 13:00 ET
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
2023-01-06 13:00 ET
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
2022-12-21 21:15 ET
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program
2022-12-19 12:00 ET
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
2022-12-18 21:00 ET
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th
2022-11-03 12:00 ET
Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results
2022-09-07 12:00 ET
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
2022-08-31 12:00 ET
Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis
2022-08-04 12:00 ET
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
2022-06-25 13:00 ET
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
2022-06-06 12:00 ET
Madrigal Pharmaceuticals Supports International NASH Day on June 9
2022-06-02 12:00 ET
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
2022-05-17 12:00 ET
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
2022-05-09 10:30 ET
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results
2022-04-28 12:00 ET
Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9
2022-03-09 21:30 ET
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
2022-02-24 13:00 ET
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results
2022-01-31 12:00 ET
Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health
2022-01-30 21:00 ET
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st
2022-01-10 13:00 ET
Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer
2021-12-30 13:00 ET
Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
2021-11-23 12:00 ET
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
2021-11-12 13:00 ET
Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® Digital Experience 2021
2021-11-04 10:50 ET
Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results
2021-10-04 10:50 ET
Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
2021-08-05 10:50 ET
Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update
2021-08-02 10:50 ET
Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer
2021-07-13 21:47 ET
Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study
2021-06-30 10:50 ET
Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom
2021-06-25 15:30 ET
Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial MAESTRO-NAFLD-1 at The International Liver Congress™ 2021
2021-06-08 10:50 ET
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
2021-05-21 13:38 ET
Madrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference
2021-05-18 13:00 ET
Madrigal Pharmaceuticals to Present at RBC Capital Markets Virtual 2021 Global Healthcare Conference on Wednesday, May 19, 2021 at 8:00 a.m. ET
2021-05-18 10:50 ET
Alex Howarth Joins Madrigal Pharmaceuticals as Chief Financial Officer
2021-05-06 10:50 ET
Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights
2021-02-25 11:50 ET
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
2020-11-05 11:50 ET
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
2020-09-03 10:50 ET
Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial
2020-08-26 10:50 ET
Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020
2020-08-06 10:50 ET
Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights
2020-05-07 10:50 ET
Madrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights
2020-04-14 10:50 ET
Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis Reduction
2020-02-26 11:50 ET
Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights
2019-12-11 04:57 ET
Madrigal Pharmaceuticals Announces Pricing of Secondary Offering
2019-12-10 21:01 ET
Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock
2019-11-11 22:30 ET
Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)
2019-11-06 11:50 ET
Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights

SEC forms

Show financial reports only

SEC form 10
2025-05-01 12:53 ET
Madrigal Pharmaceuticals reported for 2025 q1
SEC form 8
2025-05-01 11:02 ET
Madrigal Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-01 11:02 ET
Madrigal Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Madrigal Pharmaceuticals reported for 2025 q1
SEC form 10
2025-02-26 09:09 ET
Madrigal Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-26 07:05 ET
Madrigal Pharmaceuticals reported for 2024 q4
SEC form 8
2025-02-26 07:05 ET
Madrigal Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-26 00:00 ET
Madrigal Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Madrigal Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Madrigal Pharmaceuticals published news for 2024 q4
SEC form 10
2024-10-31 09:02 ET
Madrigal Pharmaceuticals reported for 2024 q3
SEC form 8
2024-10-31 07:05 ET
Madrigal Pharmaceuticals published news for 2024 q3
SEC form 8
2024-10-31 07:05 ET
Madrigal Pharmaceuticals reported for 2024 q3
SEC form 10
2024-10-31 00:00 ET
Madrigal Pharmaceuticals reported for 2024 q3
SEC form 10
2024-08-07 08:58 ET
Madrigal Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-07 07:06 ET
Madrigal Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-07 07:06 ET
Madrigal Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-07 00:00 ET
Madrigal Pharmaceuticals reported for 2024 q2
SEC form 10
2024-05-07 09:00 ET
Madrigal Pharmaceuticals reported for 2024 q1
SEC form 8
2024-05-07 07:06 ET
Madrigal Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-07 07:06 ET
Madrigal Pharmaceuticals reported for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Madrigal Pharmaceuticals reported for 2024 q1
SEC form 8
2024-02-28 07:01 ET
Madrigal Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-28 07:01 ET
Madrigal Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-28 06:32 ET
Madrigal Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Madrigal Pharmaceuticals published news for 2023 q4
SEC form 8
2023-11-06 08:31 ET
Madrigal Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-06 06:10 ET
Madrigal Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Madrigal Pharmaceuticals reported for 2023 q3
SEC form 6
2023-08-08 08:00 ET
Madrigal Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-08 06:50 ET
Madrigal Pharmaceuticals reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Madrigal Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Madrigal Pharmaceuticals reported for 2023 q2
SEC form 6
2023-07-17 08:00 ET
Madrigal Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-30 08:00 ET
Madrigal Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-16 19:00 ET
Madrigal Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-16 18:54 ET
Madrigal Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Madrigal Pharmaceuticals reported for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Madrigal Pharmaceuticals reported for 2023 q1
SEC form 6
2023-03-03 16:17 ET
Madrigal Pharmaceuticals published news for 2022 q4
SEC form 6
2023-02-23 08:02 ET
Madrigal Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-23 06:32 ET
Madrigal Pharmaceuticals reported for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-09 17:01 ET
Madrigal Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-10 17:00 ET
Madrigal Pharmaceuticals published news for 2022 q4
SEC form 6
2022-12-23 07:00 ET
Madrigal Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-19 08:42 ET
Madrigal Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-03 08:56 ET
Madrigal Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-03 08:01 ET
Madrigal Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q3
SEC form 6
2022-08-04 06:33 ET
Madrigal Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-04 06:31 ET
Madrigal Pharmaceuticals reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q2
SEC form 6
2022-06-17 12:33 ET
Madrigal Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-09 12:55 ET
Madrigal Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-09 10:22 ET
Madrigal Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-09 06:33 ET
Madrigal Pharmaceuticals published news for 2022 q1
SEC form 8
2022-05-09 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-09 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-02 11:40 ET
Madrigal Pharmaceuticals published news for 2022 q1
SEC form 10
2022-02-24 13:39 ET
Madrigal Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 08:01 ET
Madrigal Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q4
SEC form 6
2021-11-04 08:30 ET
Madrigal Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-04 06:07 ET
Madrigal Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q3
SEC form 6
2021-08-05 08:31 ET
Madrigal Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-05 06:51 ET
Madrigal Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-21 10:56 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-01 08:01 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-18 08:30 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-06 08:31 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 06:10 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-30 15:59 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 10
2021-02-25 11:05 ET
Madrigal Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-25 08:58 ET
Madrigal Pharmaceuticals published news for 2020 q4
SEC form 6
2020-11-05 09:20 ET
Madrigal Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-05 08:52 ET
Madrigal Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-05 06:06 ET
Madrigal Pharmaceuticals published news for 2020 q3